Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference30 articles.
1. EMA—European Medicines Agency. Summary of Product Characteristics Herceptin. 2010. Available at:
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000278/WC500074922.pdf
. Accessed: 27 July 2016.
2. Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim SB, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 2012;13(9):869–78. doi:
10.1016/S1470-2045(12)70329-7
.
3. Shinder GA, Paradis PE, Posman M, Mishagina N, Guay MP, Linardos D, et al. Patient and work flow and costs associated with staff time and facility usage at a comprehensive cancer centre in Quebec, Canada–a time and motion study. BMC Health Serv Res. 2012;12:370. doi:
10.1186/1472-6963-12-370
.
4. Colombo A, Solberg B, Vanderhoeft E, Ramsay G, Schouten HC. Measurement of nursing care time of specific interventions on a hematology-oncology unit related to diagnostic categories. Cancer Nurs. 2005;28(6):476–80.
5. Mache S, Schöffel N, Kusma B, Vitzthum K, Klapp BF, Groneberg DA. Cancer care and residents’ working hours in oncology and hematology departments: an observational real-time study in German hospitals. Jpn J Clin Oncol. 2011;41(1):81–6. doi:
10.1093/jjco/hyq152
.
Cited by
38 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献